ASCO 2023 | LUNAR: Tumor Treating Field (TTFields) therapy with SOC in mNSCLC following platinum failure

Ticiana Leal, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the randomized, Phase III LUNAR study (NCT02973789) assessing Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure. TTFields are electric fields that disrupt cancer cell viability, and preclinical studies have shown their potential to enhance the antitumor immune response. The study included patients who had progressed on or after platinum therapy, and they were randomized to receive TTFields therapy plus standard-of-care (SOC) treatment or SOC alone. The primary endpoint was overall survival (OS). The results showed that TTFields therapy significantly extended OS compared to SOC alone. The median OS with TTFields plus SOC was 13.2 months compared to 10.0 months with SOC alone. Notably, TTFields therapy showed improved OS in patients receiving immune checkpoint inhibitors (ICI) and numerically higher OS in the docetaxel subgroup. The incidence of adverse events (AEs) was similar between the groups, with mostly low-grade device-related AEs. These findings support the inclusion of TTFields therapy as part of second-line SOC in mNSCLC after platinum failure.This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.